Nuveen Asset Management LLC purchased a new position in TransEnterix, Inc. (NYSEAMERICAN:TRXC) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,570,342 shares of the medical instruments supplier’s stock, valued at approximately $2,136,000. Nuveen Asset Management LLC owned 0.72% of TransEnterix as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Paloma Partners Management Co purchased a new position in TransEnterix in the 2nd quarter worth approximately $27,000. Tradewinds Capital Management LLC boosted its stake in shares of TransEnterix by 1,222.2% during the 2nd quarter. Tradewinds Capital Management LLC now owns 23,800 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 22,000 shares during the last quarter. Swiss National Bank boosted its stake in shares of TransEnterix by 8.9% during the 2nd quarter. Swiss National Bank now owns 343,300 shares of the medical instruments supplier’s stock valued at $467,000 after buying an additional 28,200 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of TransEnterix by 5.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 1,093,288 shares of the medical instruments supplier’s stock valued at $1,487,000 after buying an additional 60,402 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of TransEnterix by 9.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 791,204 shares of the medical instruments supplier’s stock valued at $1,076,000 after buying an additional 66,315 shares during the last quarter.

Shares of TRXC stock traded up $0.02 on Wednesday, hitting $0.29. 77,566 shares of the stock traded hands, compared to its average volume of 2,652,374. TransEnterix, Inc. has a 1-year low of $0.25 and a 1-year high of $4.13.

TransEnterix (NYSEAMERICAN:TRXC) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01). The business had revenue of $3.64 million during the quarter, compared to analysts’ expectations of $5.13 million.

Several research firms recently issued reports on TRXC. Royal Bank of Canada lowered TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price target on the stock. in a research report on Thursday, August 8th. Zacks Investment Research lowered TransEnterix from a “hold” rating to a “sell” rating in a research report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. TransEnterix presently has an average rating of “Hold” and an average price target of $2.62.

About TransEnterix

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Recommended Story: Economic Reports

Want to see what other hedge funds are holding TRXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransEnterix, Inc. (NYSEAMERICAN:TRXC).

Institutional Ownership by Quarter for TransEnterix (NYSEAMERICAN:TRXC)

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.